AURA - NASDAQ
Aura Biosciences, Inc.
$6.88
-0.29%Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotaura
Total Debt
Last Annual Value
17.38M
3-Year CAGR
-6%
5-Year CAGR
310%
10-Year CAGR
80%
Aura Biosciences, Inc. Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Aura Biosciences, Inc. NASDAQ:AURA | 17.38M | -3.9% | 77.9% | N/A | |
 Quantum-Si incorporated NASDAQ:QSI | 4.17M | -35.2% | -12.4% | N/A | |
 Altimmune, Inc. NASDAQ:ALT | 35.69M | 276.1% | 87.6% | 43.2% | |
 Design Therapeutics, Inc. NASDAQ:DSGN | 645.00K | -40.4% | -29.2% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 64.85M | 4.1% | 4.8% | N/A | |
 Larimar Therapeutics, Inc. NASDAQ:LRMR | 4.07M | -9.8% | -7.5% | 1.3% | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 4.49M | -13.4% | N/A | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | 43.49M | 9.4% | -0.9% | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 26.20M | -5.8% | -5.4% | N/A | |
 Solid Biosciences Inc. NASDAQ:SLDB | 21.16M | -6.9% | 59.3% | N/A | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | 24.88M | -0.2% | 1.9% | -6.5% |
Aura Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your AURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.